Anesthesia and cancer recurrence: Improved understanding, but no reason for change

Anesthesia and Analgesia

Volumn 118, Issue 1, 2014, Pages 8-9

  Durieux, Marcel E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ANALGESIC AGENT; BUPIVACAINE; CELECOXIB; KETOROLAC; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; OPIATE ANTAGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL SURGERY; ANESTHESIA; APOPTOSIS; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; EDITORIAL; EPIDURAL ANESTHESIA; HUMAN; INTRAOPERATIVE PERIOD; METASTASIS; NERVE BLOCK; NONHUMAN; POSTOPERATIVE ANALGESIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REGIONAL ANESTHESIA; SURGICAL PATIENT; TUMOR CELL; TUMOR GROWTH;

EID: 84891768743     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000000026     Document Type: Editorial

References (11)

1. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006;105:660-4
2. Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, De Kock M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010;110:1630-5
3. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, Stainier A, Legrand C, Canon JL, Kremer Y, De Kock M. Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery. Ann Surg Oncol 2013
4. Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg 2010;110:1636-43
5. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI; ANZCA Trials Group Investigators. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011;342:d1491
6. Rigg JR, Jamrozik K, Myles PS, Silbert BS, Peyton PJ, Parsons RW, Collins KS; MASTER Anaethesia Trial Study Group. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet 2002;359:1276-82
7. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011;112:558-67
8. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002;62:4491-8
9. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007;97:1523-31
10. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002
11. Chang YC, Chen MJ, Hsu YW, Chen SN, Lin CH, Chen CM, Yang FM, Hu MC. Local anesthetics induce apoptosis in human breast tumor cells. Anesth Analg 2014;118:116-24